Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden.

Scandinavian journal of rheumatology·2026
Same author

Sensitive detection of plasma interferon regulatory factor-5 (IRF5) by solid-phase proximity ligation assay validates IRF5 high and low subgroups in patients with systemic lupus erythematosus.

Scandinavian journal of rheumatology·2025
Same author

The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use.

Multiple sclerosis and related disorders·2025
Same author

Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection.

QJM : monthly journal of the Association of Physicians·2024
Same author

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Health-related quality of life, anxiety, depression, beliefs of medication, and self-efficacy in individuals with severe asthma - a population-based study.

The Journal of asthma : official journal of the Association for the Care of Asthma·2023

Related Experiment Video

Updated: May 12, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Belimumab for systemic lupus erythematosus: a practice-based view.

I Parodis1, M Axelsson, I Gunnarsson

  • 1Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Stockholm, Sweden. ioannis.parodis@karolinska.se

Lupus
|April 5, 2013
PubMed
Summary

Belimumab, a new biologic therapy for systemic lupus erythematosus (SLE), effectively reduces autoantibodies and improves disease activity. This targeted treatment offers sustained benefits for SLE patients with no increased risk of serious adverse events.

More Related Videos

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Related Experiment Videos

Last Updated: May 12, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Murine Bilateral Renal Lymphadenectomy
06:31

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease impacting multiple organs.
  • B-lymphocyte hyperactivity is central to SLE pathogenesis.
  • Current SLE management requires novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of belimumab in treating active, autoantibody-positive SLE.
  • To assess belimumab's impact on immunological markers and clinical disease activity.

Main Methods:

  • Clinical trials (Phase II and two Phase III) involving patients with active SLE.
  • Belimumab administration as an add-on to standard SLE therapy.
  • Assessment of clinical indicators, immunological markers, and adverse events.

Main Results:

  • Belimumab demonstrated sustained improvement in various clinical indicators of SLE.
  • Treatment with belimumab led to reduced levels of autoantibodies and normalized complement levels.
  • Improvements were predominantly observed in musculoskeletal and mucocutaneous domains; no increased risk of serious adverse events was noted.

Conclusions:

  • Belimumab is an effective and safe biological agent for managing active, autoantibody-positive SLE.
  • This therapy normalizes key immunological parameters and alleviates disease activity in specific organ systems.
  • Further research is warranted for severe lupus nephritis and central nervous system involvement.